Pelthos Therapeutics appoints Andrew Einhorn to Board of Directors; board expands to eight

Pelthos Therapeutics Inc.

Andrew Einhorn appointed to Board effective December 23, 2025, filling newly created eighth seat.
Einhorn will serve on Audit and Compensation Committees; term until 2026 annual meeting.
Einhorn brings 40+ years of finance, capital markets, and life sciences experience.
Granted 12,000 RSUs vesting January 1, 2027, plus standard non-employee director compensation.
Board expanded from seven to eight members; Einhorn deemed independent under Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.